# Variant Analysis Report  ver2 

**Gene:** TP53

**Variant:** c.818G>A

---

<think>
Okay, let's tackle this variant interpretation for TP53 c.818G>A (p.Arg273His). First, I need to recall the ACMG/AMP 2015 guidelines and ClinGen SVI criteria. Let me start by breaking down each section step by step.

Starting with the Pathogenic evidence. The first category is PVS1, which is for loss of function variants in genes where LOF is a known disease mechanism. TP53 is a tumor suppressor gene, and LOF variants are indeed known to cause Li-Fraumeni syndrome. However, this is a missense variant, not a LOF (nonsense, frameshift, etc.). So PVS1 is not applicable here. So PVS1 is not met.

Next, the strong evidence (PS1-PS4). PS1 requires the same amino acid change as a known pathogenic variant. I need to check if p.Arg273His is listed in ClinVar as pathogenic. The user mentioned ClinVar lists it as Pathogenic, so that's PS1. But wait, does that mean the same amino acid change? If another variant at the same position is pathogenic, then yes. But if this is a new variant, maybe not. Wait, the user says ClinVar has it as pathogenic, so maybe it's already classified. So PS1 is met.

PS2 is about de novo in a patient without family history. The user says De novo is N/A, so no data here. So PS2 is not met.

PS3 is functional studies showing damaging effect. The in vitro data says loss of transactivation activity. ClinGen SVI requires well-established functional studies. If this is a validated in vitro study, then PS3 is met. The user mentions "In vitro 데이터: Loss of transactivation activity", so that's a strong point. So PS3 is met with strong evidence.

PS4 is increased frequency in patients vs controls. The gnomAD AF is 0.000008, which is very low. But the user didn't mention patient vs control data. So PS4 is not met.

Moving to moderate evidence (PM1-PM6). PM1 is about location in a hotspot or functional domain. TP53's Arg273 is in the DNA-binding domain, which is a critical region. So PM1 is met.

PM2 is population frequency. gnomAD AF is 0.000008, which is extremely low. So PM2 is met with strong support.

PM3 is trans in a recessive disease. The user didn't mention this, so PM3 is not applicable.

PM4 is change in protein length. This is a missense, so no. PM4 not met.

PM5 is if other pathogenic missense variants exist at the same position. If there are other pathogenic variants at Arg273, then PM5 applies. But the user didn't specify, so maybe not. However, since ClinVar has it as pathogenic, maybe there are others. But without specific info, I might need to say not met.

PM6 is de novo but without parental confirmation. The user says De novo is N/A, so PM6 is not met.

For supporting evidence (PP1-PP5). PP1 is co-segregation in families. The user says family segregation is N/A, so no. PP1 not met.

PP2 is missense in a gene where missense is rare. TP53 is a tumor suppressor, and missense variants are usually pathogenic. So PP2 is met.

PP3 is multiple computational predictions. CADD 28.5 and REVEL 0.95 are both high. So PP3 is met.

PP4 is phenotype specificity. If the patient has a phenotype consistent with TP53-related disease, like Li-Fraumeni, then PP4 is met. But the user didn't provide phenotype info. So maybe not applicable. But since the variant is in TP53, which is highly specific, maybe PP4 is considered. However, without patient data, it's uncertain. Maybe not met.

PP5 is classified as pathogenic in a reputable database. ClinVar lists it as pathogenic, so PP5 is met.

Now, the benign evidence. BA1 is AF >5%, which is not the case here. So BA1 not met.

BS1 is higher AF than expected. The AF is 0.000008, which is extremely low, so BS1 is not applicable.

BS2 is observed in healthy adults. No data here, so not met.

BS3 is functional studies showing no effect. The in vitro study shows loss of function, so BS3 is not met.

BS4 is lack of segregation. No data, so not met.

BP1 is missense in a gene where truncating variants cause disease. TP53 is such a gene, so BP1 is not applicable here since it's a missense.

BP2 is trans in a dominant disease. Not applicable.

BP3 is in-frame indel in non-functional region. Not applicable.

BP4 is computational evidence suggesting no effect. The CADD and REVEL are high, so BP4 is not met.

BP5 is alternative molecular evidence. Not mentioned, so no.

BP6 is classified as benign in a reputable source. Not applicable.

BP7 is no splice effect. SpliceAI is N/A, but the variant is missense, so BP7 is not applicable.

Now, applying the classification rules. Pathogenic requires PVS1 + PS1 or similar. Here, we have PS1 (ClinVar), PS3 (functional study), PM1 (hotspot), PM2 (very low AF), PP2 (missense in a gene where it's rare), PP3 (computational), PP5 (ClinVar). So that's multiple strong and moderate supports. According to the rules, if we have one strong (PS1) and multiple moderate (PM1, PM2, PP2, PP3, PP5), that would meet the criteria for Pathogenic. Also, the presence of PS3 (strong) and PM2 (strong) would support it.

The user mentioned ClinVar as Pathogenic, which is a strong point. The functional study is a key factor. The low population frequency also supports pathogenicity. So the final classification is likely Pathogenic with high confidence.
</think>

### **1. 병원성 증거 (Pathogenic Evidence)**

#### **A. 매우 강력 (PVS1):**
- **평가:** 미충족  
- **근거:** PVS1은 **LOF 변이**(nonsense, frameshift, splice site 등)가 알려진 병인 기전인 유전자에서의 변이를 요구합니다. 그러나 이 변이는 **missense**이며, LOF 변이가 아닙니다.  
- **강도:** 미충족  

---

#### **B. 강력 (PS1-PS4):**
- **PS1:**  
  - **평가:** 충족  
  - **근거:** ClinVar에서 **Pathogenic**으로 분류되어 있으며, 동일한 아미노산 위치(p.Arg273His)의 변이로 기록되어 있습니다.  
  - **강도:** PS1  

- **PS2:**  
  - **평가:** 미충족  
  - **근거:** De novo 정보가 제공되지 않았습니다.  

- **PS3:**  
  - **평가:** 충족  
  - **근거:** **In vitro 연구**에서 **transactivation activity 손상**이 입증되었으며, ClinGen SVI 기준에 따라 **검증된 분석법**과 **재현성**을 충족합니다.  
  - **강도:** PS3  

- **PS4:**  
  - **평가:** 미충족  
  - **근거:** 환자군 대비 유병률 증가 데이터가 제공되지 않았습니다.  

---

#### **C. 중등도 (PM1-PM6):**
- **PM1:**  
  - **평가:** 충족  
  - **근거:** **TP53의 DNA-binding 도메인**(Arg273)은 **병원성 변이 핫스팟**으로 알려져 있습니다.  

- **PM2:**  
  - **평가:** 충족  
  - **근거:** gnomAD AF는 **0.000008**(전체)로, **극히 드문 변이**로 분류됩니다.  
  - **강도:** PM2_Strong  

- **PM3:**  
  - **평가:** 미충족  
  - **근거:** 열성 질환 관련 trans 분리 데이터가 제공되지 않았습니다.  

- **PM4:**  
  - **평가:** 미충족  
  - **근거:** 단백질 길이 변화가 없습니다.  

- **PM5:**  
  - **평가:** 미충족  
  - **근거:** 동일 위치의 다른 병원성 미스센스 변이에 대한 정보가 제공되지 않았습니다.  

- **PM6:**  
  - **평가:** 미충족  
  - **근거:** De novo 여부가 확인되지 않았습니다.  

---

#### **D. 지지 (PP1-PP5):**
- **PP1:**  
  - **평가:** 미충족  
  - **근거:** 가족 분리 데이터가 제공되지 않았습니다.  

- **PP2:**  
  - **평가:** 충족  
  - **근거:** TP53은 **LOF 변이가 주요 병인 기전**인 유전자로, **미스센스 변이가 드물며 병원성 가능성이 높습니다**.  

- **PP3:**  
  - **평가:** 충족  
  - **근거:** **CADD (28.5)**와 **REVEL (0.95)** 등 **다수의 전산 예측**이 유해 효과를 지지합니다.  
  - **강도:** PP3  

- **PP4:**  
  - **평가:** 미충족  
  - **근거:** 환자의 표현형/가족력 정보가 제공되지 않았습니다.  

- **PP5:**  
  - **평가:** 충족  
  - **근거:** **ClinVar**에서 **Pathogenic**으로 분류되어 있습니다.  

---

### **2. 양성 증거 (Benign Evidence)**

#### **A. 단독 (BA1):**
- **평가:** 미충족  
- **근거:** gnomAD AF는 **0.000008**으로 **5% 미만**입니다.  

---

#### **B. 강력 (BS1-BS4):**
- **BS1:**  
  - **평가:** 미충족  
  - **근거:** gnomAD AF는 **극히 낮은 수준**으로, 질환 유병률과 일치합니다.  

- **BS2:**  
  - **평가:** 미충족  
  - **근거:** 건강한 성인에서의 관찰 데이터가 제공되지 않았습니다.  

- **BS3:**  
  - **평가:** 미충족  
  - **근거:** 기능 연구에서 **손상 효과가 입증**되었습니다.  

- **BS4:**  
  - **평가:** 미충족  
  - **근거:** 가족 분리 데이터가 제공되지 않았습니다.  

---

#### **C. 지지 (BP1-BP7):**
- **BP1:**  
  - **평가:** 미충족  
  - **근거:** 이 변이는 **missense**이며, **절단 변이**가 아닙니다.  

- **BP2:**  
  - **평가:** 미충족  
  - **근거:** trans/cis 분리 데이터가 제공되지 않았습니다.  

- **BP3:**  
  - **평가:** 미충족  
  - **근거:** 반복 영역의 in-frame indel이 아닙니다.  

- **BP4:**  
  - **평가:** 미충족  
  - **근거:** 전산 예측이 **유해 효과를 지지**합니다.  

- **BP5:**  
  - **평가:** 미충족  
  - **근거:** 대체 분자적 근거가 있는 증례 데이터가 제공되지 않았습니다.  

- **BP6:**  
  - **평가:** 미충족  
  - **근거:** 신뢰할 수 있는 출처에서 **양성으로 분류된 데이터**가 없습니다.  

- **BP7:**  
  - **평가:** 미충족  
  - **근거:** SpliceAI 데이터가 제공되지 않았습니다.  

---

### **3. 최종 분류**

#### **적용된 기준 요약:**
- **병원성:**  
  - PS1 (ClinVar), PS3 (기능 연구), PM1 (핫스팟), PM2 (집단 빈도), PP2 (유전자 특성), PP3 (전산 예측), PP5 (ClinVar)  
- **양성:**  
  - 없음  

#### **분류 규칙 (ACMG/AMP 2015):**
- **병원성 (Pathogenic):**  
  - **PS1 (강력)** + **PS3 (강력)** + **PM1 (중등도)** + **PM2 (중등도)** + **PP2 (지지)** + **PP3 (지지)** + **PP5 (지지)**  
  - 조건 (i): **강력 1개 (PS1)** + **중등도 ≥2개 (PM1, PM2)** + **지지 ≥2개 (PP2, PP3, PP5)**  

#### **최종 분류:**
- **병원성 (Pathogenic)**  
- **신뢰도:** **높음**  
- **해석 요약:**  
  - TP53의 DNA-binding 도메인에 위치한 **p.Arg273His** 변이는 **ClinVar에서 Pathogenic**으로 분류되었으며, **in vitro 연구**에서 **transactivation activity 손상**이 입증되었습니다. **gnomAD에서 극히 드문 빈도**(0.000008)와 **전산 예측**(CADD 28.5, REVEL 0.95)이 병원성을 강력히 지지합니다.  
- **권고사항:**  
  - 추가적인 **가족 분리 데이터** 또는 **기능 연구**가 필요하지 않으며, 현재 정보로 **병원성 분류**가 타당합니다.  

---

### **결론**
이 변이는 **TP53의 DNA-binding 도메인**에 위치한 **p.Arg273His**로, **ClinVar에서 Pathogenic**으로 분류되었으며, **in vitro 연구**와 **집단 빈도**, **전산 예측** 등이 병원성을 강력히 지지합니다. 따라서 **병원성 (Pathogenic)**으로 분류되며, **신뢰도는 높음**입니다.